In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 293-297

  Bernacki, R J ^a   Pera, P ^a   Gambacorta, P ^a   Brun, Y ^a   Greco, W R ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE; IRINOTECAN; PACLITAXEL; RUBITECAN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NUDE MOUSE; OVARY CANCER;

MUS MUSCULUS;

EID: 0034515317     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07046.x     Document Type: Conference Paper

References (5)

1. Plant antitumor agents. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
2. The camptothecins
3. Characterization of a synergistic interaction between a thymidylate synthase inhibitor, ZD 1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP 1100: Mechanisms and clinical implications
4. New colorimetric cytotoxicity assay for anticancer-drug screening
5. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: The critical role of polyglutamylation